PortalPublikationenResults from a multicenter, noninterventional registry study...

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Standard

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. / Morris, Curly; Chabannon, Christian; Masszi, Tamas; Russell, Nigel; Nahi, Hareth; Kobbe, Guido; Krejci, Marta; Auner, Holger W; Pohlreich, David; Hayden, Patrick; Basak, Grzegorz W; Lenhoff, Stig; Schaap, Nicolaas; van Biezen, Anja; Knol, Cora; Iacobelli, Simona; Liu, Qianying; Celanovic, Marina; Garderet, Laurent; Kröger, Nicolaus.

in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 2, 02.2020, S. 356-366.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Morris, C, Chabannon, C, Masszi, T, Russell, N, Nahi, H, Kobbe, G, Krejci, M, Auner, HW, Pohlreich, D, Hayden, P, Basak, GW, Lenhoff, S, Schaap, N, van Biezen, A, Knol, C, Iacobelli, S, Liu, Q, Celanovic, M, Garderet, L & Kröger, N 2020, 'Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor', BONE MARROW TRANSPL, Jg. 55, Nr. 2, S. 356-366. https://doi.org/10.1038/s41409-019-0676-0

APA

Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H. W., Pohlreich, D., Hayden, P., Basak, G. W., Lenhoff, S., Schaap, N., van Biezen, A., Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L., & Kröger, N. (2020). Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. BONE MARROW TRANSPL, 55(2), 356-366. https://doi.org/10.1038/s41409-019-0676-0

Vancouver

Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G et al. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. BONE MARROW TRANSPL. 2020 Feb;55(2):356-366. https://doi.org/10.1038/s41409-019-0676-0

Bibtex

@article{ec83b026157e41fb84e238b0d61e0ef4,
title = "Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor",
abstract = "Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.",
author = "Curly Morris and Christian Chabannon and Tamas Masszi and Nigel Russell and Hareth Nahi and Guido Kobbe and Marta Krejci and Auner, {Holger W} and David Pohlreich and Patrick Hayden and Basak, {Grzegorz W} and Stig Lenhoff and Nicolaas Schaap and {van Biezen}, Anja and Cora Knol and Simona Iacobelli and Qianying Liu and Marina Celanovic and Laurent Garderet and Nicolaus Kr{\"o}ger",
year = "2020",
month = feb,
doi = "10.1038/s41409-019-0676-0",
language = "English",
volume = "55",
pages = "356--366",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

AU - Morris, Curly

AU - Chabannon, Christian

AU - Masszi, Tamas

AU - Russell, Nigel

AU - Nahi, Hareth

AU - Kobbe, Guido

AU - Krejci, Marta

AU - Auner, Holger W

AU - Pohlreich, David

AU - Hayden, Patrick

AU - Basak, Grzegorz W

AU - Lenhoff, Stig

AU - Schaap, Nicolaas

AU - van Biezen, Anja

AU - Knol, Cora

AU - Iacobelli, Simona

AU - Liu, Qianying

AU - Celanovic, Marina

AU - Garderet, Laurent

AU - Kröger, Nicolaus

PY - 2020/2

Y1 - 2020/2

N2 - Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

AB - Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.

U2 - 10.1038/s41409-019-0676-0

DO - 10.1038/s41409-019-0676-0

M3 - SCORING: Journal article

C2 - 31534192

VL - 55

SP - 356

EP - 366

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -